Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin
lymphoma. 10–20% of the patients present with bone marrow (BM) involvement which …

Background: Diffuse large B-cell lymphoma (DLBCL) used to be defined as germinal center
B-like and non-germinal center B-like subtypes, associated with different prognoses, but the …

Identification of biomarkers is crucial in guiding the treatment decision and improving the
future outcomes of DLBCL. The aim of the current study is to detect the biochemical and …

Background: Diffuse large B-cell Lymphoma (DLBCL) is stratified histologically as GCB and
ABC phenotypes based on Hans algorithm. Besides this categorization, there is a paucity of …

Background: Expression patterns of microRNAs in serum are involved in potentially
biomarkers for various diseases. The aim of the study was to investigate the expression level …

Background Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of tumors,
with aggressive clinical course that renders prognostication and choice of treatment strategy …

Abstract MiR-101-3p has been suggested to be implicated in the pathogenesis of
lymphoma, however little is known regarding clinicopathological significance of its …

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma.
MicroRNAs (miRNAs) are endogenous small RNA, which can regulate gene expression at …

Background EBV+ diffuse large B-cell lymphoma of the elderly (EBV+ DLBCLe) is
considered a provisional entity in the latest World Health Organization classification. It …

Background Expression patterns of micro RNA s in serum are involved in potentially non‐
invasive biomarkers for various diseases. The purpose of this study is to examine the …